reviewed april 2026|next review october 2026|88 physicians psi has verified|3 published studies
Matrixyl (Palmitoyl Pentapeptide-4)
Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS) is a palmitoylated signal peptide that mimics collagen breakdown fragments to stimulate fibroblast collagen production, one of the most commercially successful cosmetic peptides with limited independent academic validation.
Evidence landscape: 3 published studies
3 published items under this slug.
- 3 Animal
Matrixyl mimics collagen breakdown fragments (matrikines) to trigger a wound-repair response in skin cells. The KTTKS sequence was identified as a stimulatory fragment of collagen type I propeptide.
Developed by Sederma (now Ashland), Matrixyl is one of the most commercially successful cosmetic peptides. Found in thousands of skincare products worldwide.
Most clinical data comes from manufacturer-sponsored studies with small sample sizes. Independent academic replication of efficacy claims is limited.
PSI Assessment
Matrixyl brought peptide skincare into the mainstream. The published data showing wrinkle depth reduction comparable to retinol made it a landmark for cosmetic peptide science. The collagen stimulation mechanism through matrikine signaling is established and the clinical wrinkle data is real, though studies are small and mostly industry-funded. The distinction between matrikine signaling (Matrixyl) and copper delivery (GHK-Cu) is the key comparison in this space. Independent academic replication of the manufacturer efficacy claims remains limited.
One of the most commercially successful cosmetic peptides. Matrikine signaling distinct from GHK-Cu's copper delivery. Limited independent academic replication.
Matrixyl is the trade name for palmitoyl pentapeptide-4 (Pal-KTTKS), a synthetic lipopeptide developed by Sederma (now Ashland). The KTTKS sequence is a fragment of the procollagen I C-terminal propeptide. It functions as a matrikine, a collagen breakdown fragment that signals fibroblasts to produce new collagen types I, III, and IV, along with fibronectin and glycosaminoglycans (GAGs). The palmitoyl chain enhances skin penetration through the lipid barrier. Manufacturer-sponsored clinical studies report wrinkle depth reduction comparable to retinol, though sample sizes are small and independent academic validation is limited.
What the evidence supports
Matrixyl stimulates collagen production through matrikine signaling in cell culture and skin models. Palmitoylation enhances skin penetration through the lipid barrier. Commercial formulations are widely used in the skincare industry.
What is not yet established
Independent academic replication of manufacturer efficacy claims. Head-to-head comparison with GHK-Cu or retinoids for anti-aging outcomes. Whether matrikine signaling produces clinically meaningful skin improvement beyond cosmetic observation. Long-term efficacy data.
Research Evidence
The findings below cover the matrikine mechanism, clinical wrinkle data, and the independent validation gap.
Evidence by condition
Evidence dimensions across Matrixyl conditions. Collagen stimulation is established in cell culture. Clinical wrinkle data is from manufacturer studies.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Skin Aging | ||||
| Collagen Stimulation | ||||
| Wrinkle Depth |
The KTTKS sequence stimulates collagen I, III, and IV production in fibroblast cultures through matrikine signaling. Palmitoylation enhances penetration through the stratum corneum.
The matrikine mechanism is biologically established. In vitro collagen stimulation is consistent across studies. Whether in vitro stimulation translates to clinically meaningful skin improvement in vivo is less clear.
Manufacturer-sponsored clinical studies report wrinkle depth reduction with topical Matrixyl formulations. One study reported results comparable to retinol over 12 weeks.
These studies are from Sederma/Ashland. Sample sizes are small. Independent academic replication of the wrinkle reduction findings has not been published at scale.
Matrixyl uses a fundamentally different mechanism from GHK-Cu. Matrikine signaling mimics collagen breakdown fragments; GHK-Cu delivers copper and modulates over 4,000 genes. The evidence base for GHK-Cu is substantially deeper.
Both are established cosmetic peptide ingredients. GHK-Cu has 186 published studies compared to Matrixyl's more limited independent literature.
0 Human|3 Animal|0 Reviews
View all 3 indexed studiesHow Matrixyl (Palmitoyl Pentapeptide-4) Works
Matrixyl (Pal-KTTKS) is a palmitoylated pentapeptide that mimics a collagen type I breakdown fragment, signaling fibroblasts through matrikine receptors to upregulate collagen synthesis, fibronectin production, and glycosaminoglycan deposition.
When collagen in skin breaks down (from age, sun, pollution), small fragments are released. These fragments signal skin cells that repair is needed. Matrixyl mimics one of these fragments, activating repair machinery and stimulating new collagen production even when damage has not occurred.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Palmitoyl pentapeptide-4 (pal-KTTKS) is a fragment of the procollagen I C-terminal propeptide. It activates TGF-beta signaling and stimulates production of collagen I, III, and IV, as well as fibronectin and glycosaminoglycans. The palmitoyl group enhances skin penetration by increasing lipophilicity.
What is Matrixyl (Palmitoyl Pentapeptide-4) being studied for?
Researchers are studying Matrixyl (Palmitoyl Pentapeptide-4) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Matrixyl (Palmitoyl Pentapeptide-4) overall. This means a compound can have human studies for one condition but only animal data for another.
Skin Aging
·Animal StudiesMatrixyl stimulates collagen production through matrikine signaling. Manufacturer studies report improvements in skin thickness, firmness, and fine line reduction.
Limitations: Most clinical data is manufacturer-sponsored. Independent academic validation is limited. Head-to-head comparisons with GHK-Cu or retinoids have not been published.
Collagen Stimulation
·Animal StudiesIn vitro studies demonstrate increased collagen I, III, and IV synthesis in fibroblast cultures. The matrikine mechanism is consistent across multiple studies.
Limitations: The gap between in vitro collagen stimulation and clinically meaningful skin improvement has not been clearly quantified.
Wrinkle Depth
·Animal StudiesManufacturer-sponsored studies report measurable wrinkle depth reduction with sustained topical application.
Limitations: Small sample sizes. Manufacturer-sponsored. Cosmetic endpoints rather than histological confirmation of dermal collagen changes.
Safety and Regulatory Status
FDA Status: Not a regulated pharmaceutical. Marketed as a cosmetic ingredient. No drug claims.
Availability: Widely available in over-the-counter skincare products. Found in thousands of commercial formulations worldwide.
Class context: Matrikine signal peptide. Distinct from copper peptides (GHK-Cu) and neuropeptides (Argireline, SNAP-8). One of the most commercially established cosmetic peptide ingredients.
Excellent topical safety profile with decades of commercial use. Non-irritating and non-sensitizing in dermatological testing. Gentler than retinoids.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Matrixyl (Palmitoyl Pentapeptide-4) discussion.
Comparison and Related Research
Matrixyl is most often compared with GHK-Cu (broader mechanism, deeper evidence base), palmitoyl tripeptide-1 (related matrikine in the Matrixyl 3000 formulation), and retinol (established anti-aging, more clinical data).
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Identification of the KTTKS pentapeptide sequence as a stimulatory fragment of collagen type I propeptide. This foundational study established the matrikine mechanism underlying Matrixyl: collagen breakdown fragments signal fibroblasts to produce new collagen.Katayama K et al., 1993 in J Biol Chem. View on PubMed
- 2.Double-blind clinical trial evaluating Matrixyl (palmitoyl pentapeptide-4) for wrinkle reduction. The study reported measurable improvements in wrinkle depth and skin surface roughness with topical application over 12 weeks.Robinson LR et al., 2005 in Int J Cosmet Sci. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.